Cytek BioSciences Inc [CTKB] stock prices are up 5.49% to $3.84 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CTKB shares have gain 2.40% over the last week, with a monthly amount glided 2.13%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cytek BioSciences Inc [NASDAQ: CTKB] stock has seen the most recent analyst activity on May 09, 2025, when TD Cowen downgraded its rating to a Hold but kept the price target unchanged to $4 for it. Previously, Goldman downgraded its rating to Sell on January 31, 2025, and dropped its price target to $4.50. On December 14, 2023, Stephens initiated with a Overweight rating and assigned a price target of $9 on the stock. Raymond James started tracking the stock assigning a Mkt Perform rating.
The stock price of Cytek BioSciences Inc [CTKB] has been fluctuating between $2.37 and $7.63 over the past year. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Cytek BioSciences Inc [NASDAQ: CTKB] shares were valued at $3.84 at the most recent close of the market. An investor can expect a potential return of 108.33% based on the average CTKB price forecast.
Analyzing the CTKB fundamentals
The Cytek BioSciences Inc [NASDAQ:CTKB] reported sales of 197.05M for trailing twelve months, representing a drop of -7.59%. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at -0.13%, Pretax Profit Margin comes in at -0.04%, and Net Profit Margin reading is -0.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.03 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Cytek BioSciences Inc [NASDAQ:CTKB]’s Current Ratio is 5.62. Further, the Quick Ratio stands at 4.95, while the Cash Ratio is 1.41. Considering the valuation of this stock, the price to sales ratio is 2.47, the price to book ratio is 1.29.
Transactions by insiders
Recent insider trading involved McCombe William D., Chief Financial Officer, that happened on Jun 02 ’25 when 35000.0 shares were purchased.
